Shares of BioScrip, Inc. (NASDAQ:BIOS) were up 6.1% during trading on Thursday . The stock traded as high as $2.33 and last traded at $2.27. Approximately 948,401 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 1,739,214 shares. The stock had previously closed at $2.14.

Several analysts have recently commented on BIOS shares. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 1st. ValuEngine downgraded BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “buy” rating and set a $4.00 price target (up from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and increased their price target for the company from $3.25 to $3.75 in a research report on Thursday, August 10th. Finally, Zacks Investment Research downgraded BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $3.60.

The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The business had revenue of $198.70 million during the quarter, compared to analyst estimates of $202.91 million. During the same period last year, the business posted ($0.12) earnings per share. The company’s revenue for the quarter was down 11.5% compared to the same quarter last year. analysts forecast that BioScrip, Inc. will post -0.63 earnings per share for the current fiscal year.

In other BioScrip news, Director Michael G. Bronfein sold 27,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $2.69, for a total transaction of $72,630.00. Following the sale, the director now owns 129,669 shares in the company, valued at $348,809.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel E. Greenleaf purchased 15,000 shares of the stock in a transaction on Thursday, November 9th. The shares were purchased at an average price of $2.03 per share, for a total transaction of $30,450.00. Following the transaction, the chief executive officer now directly owns 31,000 shares of the company’s stock, valued at $62,930. The disclosure for this purchase can be found here. 0.80% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gilder Gagnon Howe & Co. LLC increased its holdings in shares of BioScrip by 3.6% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 15,764,337 shares of the company’s stock worth $43,352,000 after buying an additional 553,201 shares during the period. FMR LLC increased its holdings in shares of BioScrip by 10.8% in the second quarter. FMR LLC now owns 5,323,231 shares of the company’s stock worth $14,453,000 after buying an additional 520,231 shares during the period. Vanguard Group Inc. increased its holdings in shares of BioScrip by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,495,029 shares of the company’s stock worth $12,204,000 after buying an additional 146,980 shares during the period. Alta Fundamental Advisers LLC increased its holdings in shares of BioScrip by 36.9% in the second quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after buying an additional 818,000 shares during the period. Finally, State Street Corp increased its holdings in shares of BioScrip by 10.0% in the second quarter. State Street Corp now owns 1,815,439 shares of the company’s stock worth $4,927,000 after buying an additional 165,091 shares during the period. Institutional investors and hedge funds own 83.00% of the company’s stock.

WARNING: “BioScrip, Inc. (BIOS) Shares Up 6.1%” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/18/bioscrip-inc-bios-shares-up-6-1.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.